APA (7th ed.) Citation

H, A., Y, S., SM, A., W, H., I, A., B, A. O., . . . Z, A. (2024). Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia. Journal of medical economics, 27(1), 134. https://doi.org/10.1080/13696998.2023.2299176

Chicago Style (17th ed.) Citation

H, Al-Abdulkarim, et al. "Cost-effectiveness Analysis of Upadacitinib as a Treatment Option for Patients with Rheumatoid Arthritis in the Kingdom of Saudi Arabia." Journal of Medical Economics 27, no. 1 (2024): 134. https://doi.org/10.1080/13696998.2023.2299176.

MLA (9th ed.) Citation

H, Al-Abdulkarim, et al. "Cost-effectiveness Analysis of Upadacitinib as a Treatment Option for Patients with Rheumatoid Arthritis in the Kingdom of Saudi Arabia." Journal of Medical Economics, vol. 27, no. 1, 2024, p. 134, https://doi.org/10.1080/13696998.2023.2299176.